Compare Stocks: XTLB, ANCN, and CAPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANCN Anchiano Therapeutics	$1.71 +1.8%	$21.77	$0.51 ▼ $10.55	$12.69M	0.93	3.15 million shs	30,960 shs
CAPR Capricor Therapeutics	$8.99 -0.8%	$9.72	$2.96 ▼ $40.37	$522.68M	0.72	3.05 million shs	489,083 shs
XTLB XTL Biopharmaceuticals	$2.35 -1.9%	$2.70	$2.01 ▼ $10.28	$5.57M	1.38	4,467 shs	2,996 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANCN Anchiano Therapeutics	0.00%	0.00%	0.00%	0.00%	-35.47%
CAPR Capricor Therapeutics	0.00%	+8.36%	+44.20%	-69.09%	+36.39%
XTLB XTL Biopharmaceuticals	0.00%	-6.89%	-18.35%	-15.93%	-88.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANCN Anchiano Therapeutics	$1.71 +1.8%	$21.77	$0.51 ▼ $10.55	$12.69M	0.93	3.15 million shs	30,960 shs
CAPR Capricor Therapeutics	$8.99 -0.8%	$9.72	$2.96 ▼ $40.37	$522.68M	0.72	3.05 million shs	489,083 shs
XTLB XTL Biopharmaceuticals	$2.35 -1.9%	$2.70	$2.01 ▼ $10.28	$5.57M	1.38	4,467 shs	2,996 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANCN Anchiano Therapeutics	0.00%	0.00%	0.00%	0.00%	-35.47%
CAPR Capricor Therapeutics	0.00%	+8.36%	+44.20%	-69.09%	+36.39%
XTLB XTL Biopharmaceuticals	0.00%	-6.89%	-18.35%	-15.93%	-88.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANCN Anchiano Therapeutics	0.00	N/A	N/A	N/A
CAPR Capricor Therapeutics	2.33	Hold	$30.25	234.36% Upside
XTLB XTL Biopharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XTLB, ANCN, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/11/2026	CAPR Capricor Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/31/2026	CAPR Capricor Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$2.00
7/30/2026	CAPR Capricor Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/6/2026	XTLB XTL Biopharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	$2.01 per share	N/A
CAPR Capricor Therapeutics	$22.27M	23.62	N/A	N/A	$5.53 per share	1.64
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	($0.11) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANCN Anchiano Therapeutics	-$27.12M	-$3.46	11.40	N/A	N/A	N/A	36.08%	27.40%	N/A
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
XTLB XTL Biopharmaceuticals	-$6.97M	-$0.64	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest XTLB, ANCN, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
6/30/2026	Q4 2025	XTLB XTL Biopharmaceuticals	N/A	-$0.10	N/A	-$0.10	N/A	($0.26) million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANCN Anchiano Therapeutics	N/A	3.25	3.25
CAPR Capricor Therapeutics	N/A	7.35	7.35
XTLB XTL Biopharmaceuticals	N/A	0.40	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANCN Anchiano Therapeutics	9.05%
CAPR Capricor Therapeutics	21.68%
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
ANCN Anchiano Therapeutics	6.88%
CAPR Capricor Therapeutics	9.20%
XTLB XTL Biopharmaceuticals	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANCN Anchiano Therapeutics	16	7.42 million	N/A	Not Optionable
CAPR Capricor Therapeutics	231	58.14 million	52.79 million	Optionable
XTLB XTL Biopharmaceuticals	10	2.37 million	1.68 million	Not Optionable

XTLB, ANCN, and CAPR Headlines

Recent News About These Companies

XTL Biopharmaceuticals Ltd. Sponsored ADR

July 8, 2026 | cnn.com

XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-Hours

July 1, 2026 | nasdaq.com

XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology Platform

June 30, 2026 | quiverquant.comQ

XTL Completed the Acquisition of Psyga Bio Ltd.

June 30, 2026 | globenewswire.com

XTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026

June 23, 2026 | tipranks.com

XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq

May 23, 2026 | finanznachrichten.de

XTL Announces Receipt of Staff Delist Determination from Nasdaq

May 22, 2026 | globenewswire.com

XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise

May 15, 2026 | tipranks.com

XTL Biopharmaceuticals Ltd ADR XTLB

May 14, 2026 | morningstar.comM

XTL Biopharmaceuticals Delays 20-F Amid Subsidiary Liquidation

May 3, 2026 | theglobeandmail.com

XTL Biopharmaceuticals Ltd.

May 1, 2026 | marketwatch.com

Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key

May 1, 2026 | theglobeandmail.com

XTLB stock surges 50%, breaches 200-DMA for first time in over 3 months – here’s what the acquisition of Psyga Bio brings to the table

May 1, 2026 | msn.com

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and ...

April 29, 2026 | markets.businessinsider.com

XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth

April 29, 2026 | msn.com

XTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcement

April 29, 2026 | quiverquant.comQ

XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline

April 29, 2026 | tipranks.com

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

April 29, 2026 | globenewswire.com

XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Announces ADS Ratio Change

March 21, 2026 | finanznachrichten.de

XTL Biopharmaceuticals Announces ADS Ratio Change

March 20, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XTLB, ANCN, and CAPR Company Descriptions

Anchiano Therapeutics NASDAQ:ANCN

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Capricor Therapeutics NASDAQ:CAPR

$8.99 -0.07 (-0.75%)

As of 11:20 AM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

XTL Biopharmaceuticals NASDAQ:XTLB

$2.35 -0.05 (-1.92%)

As of 11:12 AM Eastern

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XTLB, ANCN, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XTLB, ANCN, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XTLB, ANCN, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XTLB, ANCN, and CAPR Company Descriptions

Anchiano Therapeutics NASDAQ:ANCN

Capricor Therapeutics NASDAQ:CAPR

XTL Biopharmaceuticals NASDAQ:XTLB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XTLB, ANCN, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XTLB, ANCN, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XTLB, ANCN, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XTLB, ANCN, and CAPR Company Descriptions

Anchiano Therapeutics NASDAQ:ANCN

Capricor Therapeutics NASDAQ:CAPR

XTL Biopharmaceuticals NASDAQ:XTLB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools